Singapore, Oct. 28 -- The Department of Health - Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, and Novartis have announced the initiation of the Abu Dhabi Clinical Trials Hub through Novartis global Phase 3 programmes across neuroscience, cardiovascular disease, oncology, and immunology.

Announced during the Abu Dhabi Future Health Summit 2026, the milestone marks an important step in connecting Abu Dhabi's established clinical research capabilities with global clinical development programmes, creating new opportunities for local investigators and eligible patients to participate in innovative clinical research.

The milestone builds on two years of collaboration between DoH and Novartis following the Memorandru...